Condensed Consolidated Statements of Operations (USD $)	3 Months Ended		6 Months Ended		61 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013
Condensed Consolidated Statements of Operations [Abstract]
Grant awards		$ 3,110		$ 3,110	$ 585,589
Operating expenses:
Research and development	688,979	178,410	1,129,268	349,175	4,486,750
Clinical and regulatory	454,934	100,312	516,991	147,119	944,834
General and administration	438,180	360,394	706,316	586,451	3,001,842
Total operating expenses	1,582,093	639,116	2,352,575	1,082,745	8,433,426
Loss from operations	(1,582,093)	(636,006)	(2,352,575)	(1,079,635)	(7,847,837)
Interest income	1		2		689
Other expense	(60,324)	1,132	(49,962)	(528)	(58,745)
Interest expense	(31,799)	(13,856)	(60,141)	(15,615)	(279,602)
Total non-operating expenses	(92,122)	(12,724)	(110,101)	(16,143)	(337,658)
Loss from continuing operations	(1,674,215)	(648,730)	(2,462,676)	(1,095,778)	(8,185,495)
Loss from discontinued operations		(19,029)		(20,129)	(288,724)
Net loss	(1,674,215)	(667,759)	(2,462,676)	(1,115,907)	(8,474,219)
Net loss - non-controlling interest	(53,441)	(7,914)	(78,046)	(14,378)	(154,307)
Beneficial conversion charge			(2,300,000)		(2,300,000)
Net loss attributable to common stockholders	$ (1,620,774)	$ (659,845)	$ (4,684,630)	$ (1,101,529)	$ (10,619,912)
Net loss per share attributable to common stockholders-basic and diluted	$ (0.92)	$ (0.38)	$ (2.55)	$ (0.64)
Weighted-average number of common shares used in net loss per share attributable to common stockholders-basic and diluted	1,761,962	1,739,135	1,840,048	1,734,370	2,054,824